Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;18(1):91-4.
doi: 10.4103/0971-6866.96667.

Utility of MLPA in mutation analysis and carrier detection for Duchenne muscular dystrophy

Prashant K Verma  1 , Ashwin Dalal, Balraj Mittal, Shubha R Phadke
Affiliations

Utility of MLPA in mutation analysis and carrier detection for Duchenne muscular dystrophy

Prashant K Verma et al. Indian J Hum Genet. 2012 Jan.

Abstract

Context: Multiplex ligation probe amplification (MLPA) is a new technique to identify deletions and duplications and can evaluate all 79 exons in dystrophin gene in patients with Duchenne muscular dystrophy (DMD). Being semi-quantitative, MLPA is also effective in detecting duplications and carrier testing of females; both of which cannot be done using multiplex PCR. It has found applications in diagnostics of many genetic disorders.

Aim: To study the utility of MLPA in diagnosis and carrier detection for DMD.

Materials and methods: Mutation analysis and carrier detection was done by multiplex PCR and MLPA and the results were compared.

Results and conclusions: We present data showing utility of MLPA in identifying mutations in cases with DMD/BMD. In the present study using MLPA, we identified mutations in additional 5.6% cases of DMD in whom multiplex PCR was not able to detect intragenic deletions. In addition, MLPA also correctly confirmed carrier status of two obligate carriers and revealed carrier status in 6 of 8 mothers of sporadic cases.

Keywords: Duchenne and Becker muscular dystrophies; Dystrophin; carrier detection; multiplex ligation-dependent probe amplification.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
(a) Normal MLPA peaks, (b) Heterozygous deletion in exons 8-10 in a carrier female, (c) Hemizygous deletion in exon 21, (d) Hemizygous duplication in exons 11-13
See this image and copyright information in PMC

References

    1. Emery AE. Population frequencies of inherited neuromuscular diseases – a world survey. Neuromuscul Disord. 1991;1:19–29. - PubMed
    1. Darras BT, Korf BR, Urion DK. Dystrophinopathies. In: Pagon RA, Bird TC, Dolan CR, Stephens K, editors. GeneReviews [Internet] Seattle (WA): University of Washington, Seattle; 1993-1998. [updated 2008 March 21]
    1. Miller RG, Hoffman EP. Molecular diagnosis and modern management of Duchenne muscular dystrophy. Neurol Clin. 1994;12:699–725. - PubMed
    1. Chaturvedi LS, Mukherjee M, Srivastava S, Mittal RD, Mittal B. Point mutation and polymorphism in Duchenne/Becker muscular dystrophy (D/BMD) patients. Exp Mol Med. 2001;33:251–6. - PubMed
    1. Chamberlain JS, Gibbs RA, Ranier JE, Nguyen PN, Caskey CT. Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification. Nucleic Acids Res. 1988;16:11141–56. - PMC - PubMed